Back HIV/AIDS HIV/AIDS Topics HIV Prevention

AIDS 2016: PrEP Study Achieves High Engagement and Adherence Among Black Gay Men

What was described at the 21st International AIDS Conference (AIDS 2016) as the first PrEP trial devised and run by black gay men has shown that high levels of pre-exposure prophylaxis (PrEP) use, retention, and adherence can be achieved in a demonstration project if recruitment and support structures are tailored to the needs of black men who have sex with men.

alt

Read more:

AIDS 2016: Study Looks at Use of HIV PrEP Before and During Pregnancy and Breastfeeding

Truvada for pre-exposure prophylaxis (PrEP) when it was offered as an additional tool for preventing HIV infection during the pre-conception period, pregnancy, and breastfeeding, according to study findings presented at the 21st International AIDS Conference (AIDS 2016) last month in Durban and published in the July 19 online edition of the American Journal of Obstetrics and Gynecology.

alt

Read more:

Most Contraceptives Not Linked to HIV Infection, but Depo-Provera May Raise Risk

Birth control pills and some types of injectable and implanted contraceptives were not associated with an increased risk of HIV acquisition in an updated meta-analysis that included several recent studies, researchers reported in the August 5 online edition of AIDS. However, evidence continues to suggest that use of depot medroxyprogesterone acetate (DMPA or Depo-Provera) raises the likelihood of HIV infection. The World Health Organization (WHO) plans to meet soon to assess whether guidance needs to change in the light of the new findings.

alt

Read more:

Truvada PrEP for HIV Prevention Approved in European Union

The European Commission, which has authority over new drug in the European Union, has approved Truvada (tenofovir/emtricitabine) for HIV pre-exposure prophylaxis or PrEP, Gilead Sciences announced this week. While this marketing authorization allows Truvada for PrEP to be sold throughout the EU, regulatory authorities in each country have the final say over whether to approve it and national health systems will decide whether to offer PrEP widely and pay for it.

alt

Read more:

AIDS 2016: Vaginal Bacteria May Increase HIV Susceptibility and Reduce PrEP Effectiveness

Overgrowth of a certain species of vaginal bacteria was associated with a 13-fold higher likelihood of becoming infected with HIV, while another species was found to lower tenofovir levels and may contribute to reduced efficacy of pre-exposure prophylaxis (PrEP) delivered in a vaginal gel, according to a set of presentations at the 21st International AIDS Conference (AIDS 2016) last month in Durban.

alt

Read more: